NEW DELIVERY SYSTEM FROM ALZA
Palo Alto, California-based Alza Corp has announced that it is currently developing a new oral dosage drug delivery system, the "push-pill osmotic system."
Addressing security analysts at the recent Alex Brown & Sons' 17th Annual Health Care Seminar in Baltimore, Alza's chief executive, Martin Gerstel, noted that a development program for a once-daily oral formulation of Warner-Lambert's hypolipemic gemfibrozil utilizing the new push-pill delivery system is underway. The new formulation will provide 24 hours of controlled release of the drug after a single oral dosage, and it is envisaged as a follow-on to Lopid SR.
Alza reports that the oral push-pill system has been designed specifically to deliver large quantities of insoluble drugs on a once-a-day basis. The system has the capability of providing drug release at a constant rate, or of programming the drug release profile to provide delayed, patterned or pulsatile release.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze